EyePoint, Inc. Common Stock (EYPT) Stock Price
EYPTStock
$2.99−74.11%52W
Market Cap$257.77M
P/E—
PEG Ratio—
Div yield—
Beta1.69
EYPT Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-89.05%
Price vs S&P 500 (4W)-24.30%
VGM Score20.73
EYPT Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.96 | -$1.09 | -13.94%(-$0.13) | |
| Q1 2026 | -$0.81 | -$0.99 | -22.48%(-$0.18) | |
| Q4 2025 | -$0.75 | -$0.81 | -7.99%(-$0.06) | |
| Q3 2025 | -$0.77 | -$0.85 | -10.24%(-$0.08) | |
| Q2 2025 | -$0.80 | -$0.85 | -5.96%(-$0.05) |
EYPT Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.28
4.28
4.30
4.00
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
EYPTEyePoint, Inc. Common Stock | C | F | F | 92.4x | -1.9% | 41.8% | -11365.2% | $2.99 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
About EyePoint, Inc. Common Stock
EyePoint Inc is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious retinal diseases, with the goal of improving patient outcomes while reducing treatment burden and follow-up care frequency. Its pipeline includes DURAVYU, a sustained-release product candidate for retinal diseases, and EYP-2301, an early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting vascular stability in conditions like wet age-related macular degeneration.